Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Purpose: We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular milestones that would predict for overall survival (OS) and other outcomes more reliably than serial marrow cytogene...

Full description

Bibliographic Details

Published in:	Journal of Clinical Oncology Vol. 30; no. 3; pp. 232 - 239
Main Authors:	Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L, Marin, David, Ibrahim, Amr R, Lucas, Claire, Gerrard, Gareth
Format:	research Journal Article
Published:	American Society of Clinical Oncology 1/20/2012
Online Access:	View this record in EBSCOhost